BETA


2024/0021(COD) Gradual roll-out of Eudamed, information obligation in case of interruption of supply and transitional provisions for certain in vitro diagnostic medical devices

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI
Committee Opinion EMPL
Committee Opinion IMCO
Lead committee dossier:
Legal Basis:
RoP 170, TFEU 114, TFEU 168-p4

Events

2024/07/09
   Final act published in Official Journal
2024/06/13
   CSL - Draft final act
Documents
2024/06/13
   CSL - Final act signed
2024/05/30
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2024/04/25
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.

The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.

The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.

With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.

Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.

Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.

This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.

Documents
2024/04/09
   ES_PARLIAMENT - Contribution
Documents
2024/03/20
   ESC - Economic and Social Committee: opinion, report
Documents
2024/02/26
   EP - Committee referral announced in Parliament, 1st reading
2024/01/23
   EC - Legislative proposal published
Details

PURPOSE: to address risks of shortages of in vitro diagnostic medical devices in the Union and ensure the timely roll-out of Eudamed.

PROPOSED ACT: Regulation of the European Parliament and of the Council.

ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

BACKGROUND: Regulation (EU) 2017/745 (Medical Devices Regulation (MDR)) and Regulation (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation (IVDR)) of the European Parliament and of the Council set a strengthened regulatory framework for medical devices and in vitro diagnostic medical devices (IVDs).

The MDR has been applied since 26 May 2021. A transitional period has been extended by Regulation (EU) 2023/607 and will end on either 31 December 2027 or 31 December 2028, depending on the device’s risk class and subject to certain conditions.

The IVDR has applied since 26 May 2022. In January 2022, the European Parliament and the Council adopted a staggered extension of its transitional period, ranging from 26 May 2025 for high-risk IVDs to 26 May 2027 for lower-risk IVDs, and to 26 May 2028 for certain provisions concerning devices manufactured and used in health institutions.

CONTENT: this Commission proposal aims to ensure availability of safe devices, essential for healthcare systems, and protect patient care. The latest available data shows that a high number of IVDs currently on the market has not factored in the new rules (nor has been replaced by other devices), meaning that those devices would no longer be available. The number of devices which have not factored in the new rules and are not expected to transition in time is particularly high for high risk IVDs (class D). These include important tests detecting infections in the context of blood transfusions or organ donations.

Therefore, this proposal for targeted amendments addresses two urgent issues .

Ensuring the availability of in vitro diagnostics

The proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.

The changes extend the transitional periods that are applicable to ‘legacy devices’, i.e., those covered by a certificate or declaration of conformity. The additional time granted to companies depends on the type of device:

- high individual and public health risk devices such as HIV or hepatitis tests (class D) would have a transition period until December 2027;

- high individual and/or moderate public health risk devices such as cancer tests (class C), would have a transition period until December 2028;

- lower risk devices (class B such as pregnancy tests and class A sterile devices such as blood collection tubes), have a transition period until December 2029.

The proposal also introduces a requirement for manufacturers to give prior notice to authorities, as well as to distributors or health institutions, if they foresee the interruption of supply of IVDs or medical devices , which would pose risks to patient care. This measure would enable healthcare systems to have more time to take action to safeguard patient care.

More transparency on medical devices

The mandatory use of the European database on medical devices, Eudamed, is key for the effective and efficient implementation of the Medical Device and IVD Regulations. It will increase transparency in the EU, providing an overview of all medical devices available on the European market. The proposal to enable and accelerate a gradual roll-out of Eudamed and notably s peed up the launch of the parts of Eudamed that are already finalised, so that it is mandatory earlier (as from late 2025).

Lastly, this draft Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the last electronic system of Eudamed. To attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure availability of devices whose certificates have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency .

Documents

History

(these mark the time of scraping, not the official date of the change)

events/0
date
2024-01-23T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/0
date
2024-01-23T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/5
date
2024-07-09T00:00:00
type
Final act published in Official Journal
procedure/final
title
Regulation 2024/1860
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32024R1860
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/legal_basis/0
Rules of Procedure EP 170
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
events/4
date
2024-06-13T00:00:00
type
Final act signed
body
CSL
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
docs/1
date
2024-06-13T00:00:00
docs
title: 00054/2024/LEX
type
Draft final act
body
CSL
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/2
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
events/2
date
2024-04-23T00:00:00
type
Decision by committee, without report
body
EP
events/2/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
events/3
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
events/3
date
2024-05-30T00:00:00
type
Act adopted by Council after Parliament's 1st reading
body
EP/CSL
links
Research document
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Awaiting signature of act
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/2
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
events/2
date
2024-04-23T00:00:00
type
Decision by committee, without report
body
EP
events/2/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
events/3
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
events/3
date
2024-05-30T00:00:00
type
Act adopted by Council after Parliament's 1st reading
body
EP/CSL
links
Research document
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Awaiting signature of act
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
events/4
date
2024-05-30T00:00:00
type
Act adopted by Council after Parliament's 1st reading
body
EP/CSL
links
Research document
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Awaiting signature of act
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
events/4
date
2024-05-30T00:00:00
type
Act adopted by Council after Parliament's 1st reading
body
EP/CSL
links
Research document
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Awaiting signature of act
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
links
Research document
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
links
Research document
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
links
Research document
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
links
Research document
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3/summary
  • The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices.
  • The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal.
  • The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed.
  • With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability.
  • Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs.
  • This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the certificates of which have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency on the day of its publication in the Official Journal of the European Union.
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
procedure/stage_reached
Old
Awaiting Parliament's position in 1st reading
New
Awaiting Council's 1st reading position
docs/1
date
2024-04-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/3
date
2024-04-25T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0368_EN.html title: T9-0368/2024
procedure/stage_reached
Old
Awaiting Parliament's position in 1st reading
New
Awaiting Council's 1st reading position
docs/0
date
2024-03-20T00:00:00
docs
url: https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:0746)(documentyear:2024)(documentlanguage:EN) title: CES0746/2024
type
Economic and Social Committee: opinion, report
body
ESC
docs/0
date
2024-01-23T00:00:00
docs
type
Legislative proposal
body
EC
docs/1
date
2024-04-09T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2024)0043 title: COM(2024)0043
type
Contribution
body
ES_PARLIAMENT
events/2
date
2024-04-23T00:00:00
type
Decision by committee, without report
body
EP
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's position in 1st reading
docs/0
date
2024-04-09T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2024)0043 title: COM(2024)0043
type
Contribution
body
ES_PARLIAMENT
docs/0
date
2024-01-23T00:00:00
docs
type
Legislative proposal
body
EC
events/2
date
2024-04-23T00:00:00
type
Decision by committee, without report
body
EP
forecasts/0
date
2024-04-25T00:00:00
title
Vote scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's position in 1st reading
docs/0
date
2024-04-09T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2024)0043 title: COM(2024)0043
type
Contribution
body
ES_PARLIAMENT
docs/0
date
2024-01-23T00:00:00
docs
type
Legislative proposal
body
EC
events/2
date
2024-04-23T00:00:00
type
Decision by committee, without report
body
EP
forecasts/0
date
2024-04-25T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's position in 1st reading
docs/0
date
2024-04-09T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2024)0043 title: COM(2024)0043
type
Contribution
body
ES_PARLIAMENT
docs/0
date
2024-01-23T00:00:00
docs
type
Legislative proposal
body
EC
forecasts/0
date
2024-04-25T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
docs/0
date
2024-04-09T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2024)0043 title: COM(2024)0043
type
Contribution
body
ES_PARLIAMENT
docs/0
date
2024-01-23T00:00:00
docs
type
Legislative proposal
body
EC
forecasts/0
date
2024-04-23T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
forecasts/0
date
2024-04-23T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
forecasts/0
date
2024-04-23T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
forecasts/0
date
2024-04-23T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2024-04-22T00:00:00
title
Indicative plenary sitting date
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
committees
  • type: Responsible Committee body: EP committee_full: Environment, Public Health and Food Safety committee: ENVI associated: False
  • type: Committee Opinion body: EP committee_full: Employment and Social Affairs committee: EMPL associated: False opinion: False
  • type: Committee Opinion body: EP committee_full: Internal Market and Consumer Protection committee: IMCO associated: False opinion: False
events/1
date
2024-02-26T00:00:00
type
Committee referral announced in Parliament, 1st reading
body
EP
procedure/dossier_of_the_committee
  • ENVI/9/14040
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting committee decision
forecasts/0/date
Old
2024-03-11T00:00:00
New
2024-04-22T00:00:00
events/0/summary
  • PURPOSE: to address risks of shortages of in vitro diagnostic medical devices in the Union and ensure the timely roll-out of Eudamed.
  • PROPOSED ACT: Regulation of the European Parliament and of the Council.
  • ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.
  • BACKGROUND: Regulation (EU) 2017/745 (Medical Devices Regulation (MDR)) and Regulation (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation (IVDR)) of the European Parliament and of the Council set a strengthened regulatory framework for medical devices and in vitro diagnostic medical devices (IVDs).
  • The MDR has been applied since 26 May 2021. A transitional period has been extended by Regulation (EU) 2023/607 and will end on either 31 December 2027 or 31 December 2028, depending on the device’s risk class and subject to certain conditions.
  • The IVDR has applied since 26 May 2022. In January 2022, the European Parliament and the Council adopted a staggered extension of its transitional period, ranging from 26 May 2025 for high-risk IVDs to 26 May 2027 for lower-risk IVDs, and to 26 May 2028 for certain provisions concerning devices manufactured and used in health institutions.
  • CONTENT: this Commission proposal aims to ensure availability of safe devices, essential for healthcare systems, and protect patient care. The latest available data shows that a high number of IVDs currently on the market has not factored in the new rules (nor has been replaced by other devices), meaning that those devices would no longer be available. The number of devices which have not factored in the new rules and are not expected to transition in time is particularly high for high risk IVDs (class D). These include important tests detecting infections in the context of blood transfusions or organ donations.
  • Therefore, this proposal for targeted amendments addresses two urgent issues .
  • Ensuring the availability of in vitro diagnostics
  • The proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health.
  • The changes extend the transitional periods that are applicable to ‘legacy devices’, i.e., those covered by a certificate or declaration of conformity. The additional time granted to companies depends on the type of device:
  • - high individual and public health risk devices such as HIV or hepatitis tests (class D) would have a transition period until December 2027;
  • - high individual and/or moderate public health risk devices such as cancer tests (class C), would have a transition period until December 2028;
  • - lower risk devices (class B such as pregnancy tests and class A sterile devices such as blood collection tubes), have a transition period until December 2029.
  • The proposal also introduces a requirement for manufacturers to give prior notice to authorities, as well as to distributors or health institutions, if they foresee the interruption of supply of IVDs or medical devices , which would pose risks to patient care. This measure would enable healthcare systems to have more time to take action to safeguard patient care.
  • More transparency on medical devices
  • The mandatory use of the European database on medical devices, Eudamed, is key for the effective and efficient implementation of the Medical Device and IVD Regulations. It will increase transparency in the EU, providing an overview of all medical devices available on the European market. The proposal to enable and accelerate a gradual roll-out of Eudamed and notably s peed up the launch of the parts of Eudamed that are already finalised, so that it is mandatory earlier (as from late 2025).
  • Lastly, this draft Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the last electronic system of Eudamed. To attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure availability of devices whose certificates have already expired or are due to expire before 26 May 2025, to provide legal certainty for economic operators and healthcare providers, and for reasons of consistency as regards the amendments to both Regulations, this Regulation should enter into force as a matter of urgency .
forecasts
  • date: 2024-03-11T00:00:00 title: Indicative plenary sitting date
docs/0/docs/0
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2024&nu_doc=0043
title
EUR-Lex
events/0/docs/0
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2024&nu_doc=0043
title
EUR-Lex